DNA Methylation Biomarker Discovery for Aging-Related Obesity
Technology Platforms & Expertise
Online Inquiry

DNA Methylation Biomarker Discovery for Aging-Related Obesity


Aging is a risk factor for many chronic diseases, including obesity. Obesity plays an important role in certain metabolic diseases and can lead to the development of many associated comorbidities. Studies have identified epigenetic changes involved in aging, the most studied being DNA methylation, which may be a key factor involved in the obesity process. DNA methylation modifications affect gene activity, then analysis of DNA methylation marks specific to obesity diseases may be an effective way to understand the molecular mechanisms of obesity and how to control it.

CD BioSciences can provide DNA methylation biomarker discovery services for aging-related obesity. We help our clients explore obesity epigenomic patterns, mainly based on DNA methylation analysis, which will help to develop effective preventive measures against obesity development.

DNA Methylation Biomarker Discovery for Aging-Related Obesity

Our DNA Methylation Biomarker Discovery Services for Aging-Related Obesity

We use genome-wide analysis techniques for comprehensive exploration and screening to facilitate the discovery of DNA methylation biomarkers for aging-related obesity. Through genome-wide techniques, we can compare blood and other cells/tissues from normal versus obese samples to explore potential DNA methylation biomarkers across the genome.

  • Sample Collection
    We collect samples encompassing a spectrum of obesity phenotypes from aging individuals, including normal weight, overweight, and obese. We ensure relevant clinical and phenotypic data are collected alongside the samples to facilitate correlation analyses.
  • Genome-wide DNA methylation analysis
    By employing DNA methylation analysis methods, such as bisulfite sequencing and methylation array profiling, we scrutinize the intricate DNA methylation patterns associated with aging-related obesity. Our exhaustive analysis enables the comprehensive identification of differential methylation signatures, shedding light on the epigenetic dynamics underlying obesity in aging populations.
  • Data analysis
    Our bioinformatics experts employ sophisticated algorithms and statistical tools to rigorously analyze the vast volumes of DNA methylation data obtained from aging-related obesity samples. Through meticulous data interpretation, we identify candidate DNA methylation biomarkers that exhibit robust correlations with obesity onset, progression, and associated metabolic dysregulation.
  • Validation and replication
    We validate the identified differentially methylated CpG sites or regions and their association with aging-related obesity using independent samples. Replicate the findings in different cohorts to ensure robustness and reproducibility.

Service Features

We can help you increase your chances of obtaining new biomarker discoveries by allowing us to analyze your samples to provide reliable and reproducible data that directly identifies obesity-associated DNA methylation.

  • Data privacy. We guarantee control of samples, data, and results to ensure data security.
  • Expert support. Our professional and experienced experts work with clients to solve problems and discuss results.
  • Joint decisions. We prepare and set up the research protocol and equipment jointly with you.
  • Faster feedback. We deliver fast results and innovative insights for your needs.

Our Standardized Workflow

DNA Methylation Biomarker Discovery for Aging-Related Obesity

  • First, send us your samples and we will set up a protocol based on your research needs.
  • Then we have our professional team perform in-house analysis to help you screen for DNA methylation markers associated with obesity.
  • Then you will receive the overall study result, raw data, marker identification, and analysis report. If needed, the results can be discussed with our experts.
  • Finally, you can select the most promising candidate markers of interest for final validation.

CD BioSciences is always exploring and updating innovative technologies that bring benefits to DNA methylation analysis assays. If you have a relevant research idea, please contact us and we will be happy to assist you.


  1. Stunnenberg HG, et al. Genome-wide epigenomic profiling for biomarker discovery. Clinical Epigenetics, 2016, 8 (1).
  2. Samblas M, et al. DNA methylation markers in obesity, metabolic syndrome, and weight loss. Epigenetics, 2019: 1-24.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.